Emerging Targeted Protein Degradation Tools for Innovative Drug Discovery: from Classical PROTACs to the Novel and Beyond.

Yue Zhong,Fanglian Chi,Hanyu Wu,Yunxiao Liu,Zhancheng Xie,Wenlong Huang,Wei Shi,Hai Qian
DOI: https://doi.org/10.1016/j.ejmech.2022.114142
IF: 7.088
2022-01-01
European Journal of Medicinal Chemistry
Abstract:Targeted protein degradation technology has evolved a brand-new therapeutic modality from an innovative drug discovery perspective. Though the classical PROTACs has pioneered the way for protein degraders, certain inherent defects such as poor druggability, uncontrollable catalysis caused off-targets, and limited E3 ubiquitin ligases available constitute obstacles that impede further advances. Recent medicinal chemists have preferred to investigate a type of optimized degraders beyond the classical PROTACs, bypassing such disadvantages to better facilitate targeted protein degradation. In this perspective, we comprehensively spotlighted the emerging approaches and techniques applied to the targeted protein degradation, specifically the PROTACs-derived strategies and other alternatives to realize protein degradation via proteasome or lysosome. Besides, contemporary confronted opportunities as well as challenges were further analyzed, with the aim to guide future discovery of novel protein degraders.
What problem does this paper attempt to address?